Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financial-reporting
Related Tickers: AQST
TL;DR
AQST filed a routine 8-K, mostly exhibits. No major news.
AI Summary
On February 12, 2025, Aquestive Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No new financial figures or significant business updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Aquestive Therapeutics is providing routine updates and disclosures to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard disclosure of financial statements and exhibits, not indicating any immediate material risks or changes.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- 0001398733 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 208623253 (company) — IRS Number
- DE (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 30 Technology Drive (company) — Business Address Street 1
- Warren (company) — Business Address City
- NJ (company) — Business Address State
- 07059 (company) — Business Address Zip
FAQ
What is the primary purpose of this 8-K filing by Aquestive Therapeutics?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of February 12, 2025.
What is Aquestive Therapeutics, Inc.'s principal executive office address?
Aquestive Therapeutics, Inc.'s principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.
When was Aquestive Therapeutics, Inc. incorporated?
Aquestive Therapeutics, Inc. was incorporated in Delaware.
What was Aquestive Therapeutics' former company name?
Aquestive Therapeutics' former company name was MonoSol Rx, Inc.
What is the SIC code for Aquestive Therapeutics?
The Standard Industrial Classification (SIC) code for Aquestive Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-02-12 07:22:34
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20250212.htm (8-K) — 27KB
- a2025-2x10aaaaimeetingda.htm (EX-99.1) — 15KB
- a2025-2x10aaaaimeetingda001.jpg (GRAPHIC) — 217KB
- a2025-2x10aaaaimeetingda002.jpg (GRAPHIC) — 181KB
- a2025-2x10aaaaimeetingda003.jpg (GRAPHIC) — 276KB
- a2025-2x10aaaaimeetingda004.jpg (GRAPHIC) — 298KB
- a2025-2x10aaaaimeetingda005.jpg (GRAPHIC) — 90KB
- 0001628280-25-005018.txt ( ) — 1632KB
- aqst-20250212.xsd (EX-101.SCH) — 2KB
- aqst-20250212_lab.xml (EX-101.LAB) — 21KB
- aqst-20250212_pre.xml (EX-101.PRE) — 12KB
- aqst-20250212_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On February 12, 2025, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing that multiple presentations highlighting the results from the investigational use of Anaphylm, its epinephrine sublingual film product candidate or the treatment of severe allergic reaction, including anaphylaxis, will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting which is being held from February 28 - March 3, 2025, in San Diego, California. The abstracts are available online at https://annualmeeting.aaaai.org/ as well as on the Company's website on the Scientific Events page of the investor section. The press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Press Release, dated February 12, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 12, 2025 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer